Search the Newsreel

Tyro Payments (ASX:TYR) Advances 3.05% as Turnover Nears One Million Shares

BlackRock (ATYR holder) reports 1.8% beneficial stake in aTYR PHARMA INC

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a passive beneficial ownership of 1,725,072 shares of aTYR PHARMA INC (ATYR) common stock, which represents 1.8% of the class. BlackRock maintains sole voting and dispositive power over these shares. The filing clarifies that while …

Tyra Biosciences Inc (TYRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey attempts to provide a revenue breakdown for Tyra Biosciences Inc (TYRA), covering business segments, regional revenue, and profit contribution. However, the company has not yet disclosed the relevant financial data, leading to an empty report. The article essentially states that …

Tyra Biosciences Inc (TYRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Tyra Biosciences Inc (TYRA) stock, evaluating various indicators and moving averages. It summarizes the signals from MACD, RSI, KDJ, and others, indicating a neutral stance overall, with specific buy and sell signals from different metrics. The analysis …

Tyra Biosciences Inc (TYRA) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Tyra Biosciences Inc (TYRA) focusing on its dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years, indicating no recent dividend payouts or stock splits. The financial snapshot …

aTyr Pharma Inc (ATYR) Cash Flow

This article provides a detailed historical cash flow statement for aTyr Pharma Inc (ATYR), covering quarterly and annual data from FY2013Q4 to FY2026Q1 across operating, investing, and financing activities. It also includes frequently asked questions defining key cash flow metrics and detailing ATYR's specific …

Tyra Biosciences Inc (TYRA) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Tyra Biosciences Inc (TYRA), focusing on its P/E and P/B ratios. However, it indicates that relevant data for these metrics have not yet been disclosed by the company. The page also presents current stock performance and market …

Tyra Biosciences Inc (TYRA) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Tyra Biosciences Inc (TYRA), listing major shareholders like RA Capital Management, LP, Nextech Invest, Ltd., and Alta Partners with their respective proportions. It also breaks down shareholder types, institutional holdings over various reporting periods, and related ETF …

Tyra Biosciences Inc (TYRA) Cash Flow

This article provides a detailed historical cash flow statement for Tyra Biosciences Inc (TYRA), covering quarterly and annual data for operating, investing, and financing activities. It presents financial figures such as net income, operating cash flow, capital expenditures, and free cash flow, along with …

Tyra Biosciences Inc (TYRA) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Tyra Biosciences Inc (TYRA), detailing various metrics related to volatility, financial risk, and investment risk. It includes data points such as Beta, Value at Risk (VaR), maximum drawdown, daily returns, Sharpe Ratio, and liquidity. The report offers …

Tyra Biosciences Inc|Price:30.630|Chg%:-0.170

This article provides an overview of Tyra Biosciences Inc. (TYRA) stock, showing its current price, change, and market capitalization. It highlights that no stock score is available due to insufficient data but details how TradingKey generates its comprehensive stock scores, covering financial health, valuation, …

aTyr Pharma, Inc. Revenue Breakdown – NASDAQ:ATYR

aTyr Pharma, Inc. (NASDAQ: ATYR) generated $190,000 USD in revenue last year, primarily from its Efzofitimod segment. This figure is a decrease from $235,000 USD the previous year, with the United States being the sole contributor to both years' revenues. The article provides a …

aTyr Pharma Ord Shs|Price:18.500|Chg%:-0.530

aTyr Pharma Ord Shs (LIFE) closed at $18.50, down 2.79%. The company shows strong fundamentals and high growth potential, despite a weak stock market performance over the past month. Analysts rate the stock as "Buy" with a target price of $28.00, suggesting a 47.14% …

Apollo Tyres Limited. Revenue Breakdown – NSE:APOLLOTYRE

LIFE stock trades quietly as aTyr Pharma focuses on R&D and recent loss narrows

aTyr Pharma Inc. (LIFE) is a clinical-stage biotechnology company focused on immune-modulating therapeutics. The company's latest annual results show lower revenue of $0.5 million but a narrowed net loss of $26.0 million, down from $30.0 million previously, indicating progress in cost management. Despite limited …

Tyra Biosciences (TYRA) Proxy filing Summary

Tyra Biosciences is holding its Annual Meeting on May 28, 2026, virtually. Shareholders will vote on the election of three Class II directors and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December …

Tyra Biosciences (TYRA) Q4 2025 earnings summary

Tyra Biosciences (TYRA) reported its Q4 2025 earnings, highlighting a strategic focus on three late-stage clinical studies for its dabogratinib program and an enhanced leadership team. Financially, the company ended 2025 with $256.0 million in cash, providing a runway through at least 2027, despite …

Tyra Biosciences (TYRA) Bank of America Global Healthcare Conference 2026 Summary

Tyra Biosciences presented at the Bank of America Global Healthcare Conference 2026, highlighting the advancement of its highly selective FGFR3 inhibitor, dabogratinib, into late-stage development for three potential blockbuster indications: intermediate-risk NMIBC, UTUC, and achondroplasia. The company anticipates pivotal data readouts, including a 70% …

Jennison Associates LLC Buys Shares of 632,432 Tyra Biosciences, Inc. $TYRA

H.C. Wainwright Maintains ATyr Pharma(ATYR.US) With Hold Rating

H.C. Wainwright has reiterated its Hold rating for ATyr Pharma (ATYR.US). This indicates that the analyst firm recommends investors maintain their current position in the stock. The decision reflects the firm's current assessment of the company's financial outlook and market performance.

Tyro Payments (ASX:TYR) Share Price Rises: Here's What's Behind the Move

Tolins Tyres subsidiary buys plant for capacity expansion

APOLLOTYRE Forecast — Price Target — Prediction for 2027

ATYR Forecast — Price Target — Prediction for 2027

Stamford Tyres Corporation Limited announces Annual dividend, payable on September 22, 2026

Tyro Payments (ASX:TYR) Falls Today as Fintech Stock Faces Fresh Pressure

Styrenix Performance Materials to host virtual investor meet on June 22

Apollo Tyres (NSEI:APOLLOTYRE) Stock Gets Fair Value Trim On Slight Margin Assumption Cut

Tolins Tyres FY26 net profit falls 7.7% on margin pressure

Tolins Tyres Consolidated March 2026 Net Sales at Rs 77.99 crore, up 12.17% Y-o-Y

Tolins Tyres Standalone March 2026 Net Sales at Rs 45.57 crore, up 17.26% Y-o-Y

Statutory Profit Doesn't Reflect How Good Apollo Tyres' (NSE:APOLLOTYRE) Earnings Are

Apollo Tyres, Kaynes, Tata Capital, United Breweries hit 52-week lows

Styrenix Consolidated March 2026 Net Sales at Rs 826.10 crore, down 12.09% Y-o-Y

Styrenix Performance Materials FY26 Results: Net Profit ₹234.27 Cr, Q4 EBITDA Margin Expands to 19.2%

Why Apollo Tyres’ strong quarter may not mark a turning point